Company Overview - Coeptis Therapeutics Holdings, Inc. is a next-generation technology and biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [3][4] - The company has a therapeutic portfolio that includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [4] - Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [4] Recent Developments - Coeptis has filed a registration statement on Form S-4 with the SEC related to a proposed merger agreement with Z Squared Inc. [1][2] - The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction, which has not yet become effective [2] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [5] Z Squared Overview - Z Squared Inc. is focused on digital asset compute mining, primarily generating Dogecoin (DOGE) and other digital assets like Litecoin, with a market cap of $20 billion [7]

Core Insights - SNAP Biosciences, a subsidiary of Coeptis Therapeutics, has entered into a licensing agreement with Monarch Therapeutics to develop and commercialize its Snap-Car NK cell therapy platform in oncology using Monarch's small molecule adaptor technology [1][4]. Group 1: Licensing Agreement - The agreement allows SNAP Biosciences to utilize Monarch's small-molecule adaptor technology, enhancing the functionality of the Snap-Car universal CAR-based receptor platform [2]. - Monarch's adaptor technology enables SNAP-CAR cells to be directed by small molecules, improving precision, flexibility, and modular potential across various therapeutic areas [2][3]. Group 2: Technology and Innovation - The integration of Monarch's small molecule adaptors allows Snap-Car NK cells to target multiple tumor antigens and modulate their activity in real-time, addressing tumor heterogeneity and antigen escape challenges [3]. - This collaboration aims to develop more potent, flexible, and scalable NK therapies for difficult-to-treat cancers [4]. Group 3: Financial Terms - Under the agreement, Monarch will receive an upfront licensing payment, future development milestone payments, and royalties on net sales [4]. Group 4: Company Background - Monarch Therapeutics is a pre-clinical stage biotechnology company focused on next-generation immunotherapies, particularly in solid tumors [5]. - SNAP Biosciences specializes in developing Snap-Car, a universal CAR cell therapy that allows programmable antigen targeting [6]. - Coeptis Therapeutics Holdings, Inc. focuses on innovative cell therapy platforms for cancer and other diseases, aiming to improve patient outcomes through advanced research and development [7].

Corporate Transactions and Partnerships - The company completed a reverse merger with Coeptis Therapeutics, Inc., which is now the accounting acquirer, affecting the financial condition and results of operations [138]. - The company paid approximately $570,000 in cash and issued 4,000,000 shares of common stock to Deverra Therapeutics as part of an exclusive licensing arrangement, totaling $4,937,609 in consideration [160]. - A Shared Services Agreement was established with Deverra to collaborate on the development of GEAR and SNAP-CAR platforms for six months [161]. - The company has entered into strategic partnerships to co-develop therapies for the auto-immune and oncology markets, focusing on innovative products and technologies [146]. - The company has a 50% ownership interest in the CD38-Diagnostic and CD38-GEAR-NK product candidates, with revenue sharing agreements in place [158]. - The company has divested several ANDA products to a larger generic pharmaceutical manufacturer, shifting focus away from generic product commercialization [146]. Market Opportunities and Product Development - The global multiple myeloma market was valued at $19.48 billion in 2018 and is projected to reach $31 billion by 2026, indicating significant market opportunity for the CD38-GEAR-NK product [151]. - The CD38-Diagnostic has been classified as a Class II device by the FDA, allowing for better planning and execution of future development activities [155]. - The company has abandoned all activities and ownership pertaining to two anti-hypertension products launched in 2020 due to the COVID-19 pandemic's impact on sales [146]. - The company has ceased prioritizing the development of CPT60621 and is negotiating a buy-out of remaining ownership rights with Vici Health Sciences [162]. Financial Performance and Expenses - The company generated minimal revenue primarily from consulting arrangements and product sales, with no significant revenue expected for at least the next two years [167][170]. - Operating expenses increased from $2,922,383 in Q1 2024 to $4,074,702 in Q1 2025, driven by higher professional services and stock-based compensation expenses [171]. - Cash and cash equivalents rose from $1,029,244 in Q1 2024 to $4,268,368 in Q1 2025, indicating improved liquidity for operational funding [175]. - The company anticipates increased general and administrative expenses as it expands headcount to support business growth [168]. - Research and development costs are expected to rise in alignment with new strategic initiatives and collaborations [169]. - Interest expense decreased from $200,505 in Q1 2024 to $71,491 in Q1 2025 due to the satisfaction of the Purple Biotech convertible note [173]. - The change in fair value of derivative liabilities showed a significant increase from $34,875 in Q1 2024 to $596,120 in Q1 2025, reflecting market volatility and share price changes [174]. Operational Challenges - The company continues to face operational challenges due to the COVID-19 pandemic, impacting the launch and sales of its products [147]. Technological Advancements - The company acquired NexGenAI Affiliates Network Platform, enhancing its capabilities in AI-powered marketing and digital services [164][165]. - The company plans to utilize proprietary automation technologies to streamline client outreach and digital marketing operations [166].

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)’s merger with Z Squared Inc. If you are a Coeptis shareholder, click here to learn more about your legal rights and options. Pacific Premier Bancorp, Inc. (NASDAQ: PPBI)’s sale to Columbia Banking System, Inc. ...

Group 1 - Monteverde & Associates PC is investigating Coeptis Therapeutics Holdings, Inc. regarding its proposed merger with Z Squared Inc., where Z Squared shareholders will receive equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines [1] - Monteverde & Associates PC has a successful track record in recovering millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] - The firm operates from the Empire State Building in New York City and emphasizes its national class action securities litigation capabilities [2][3] Group 2 - The firm encourages shareholders with concerns about Coeptis Therapeutics to seek additional information free of charge [3] - Monteverde & Associates PC highlights its litigation experience, including cases that have reached the U.S. Supreme Court [2]

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. and Z Squared Inc. have entered into a definitive merger agreement, resulting in Z Squared becoming a wholly-owned subsidiary of Coeptis, with a focus on Dogecoin mining and a planned spin-out of Coeptis' biopharmaceutical operations [1][5][10] Company Overview - Coeptis Therapeutics is a biopharmaceutical and technology company that develops innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [1][6] - Z Squared Inc. specializes in digital asset mining, primarily focusing on Dogecoin, which has a market capitalization exceeding $20 billion [2][10] Merger Details - The merger will involve a wholly-owned subsidiary of Coeptis merging with Z Squared, with Z Squared shareholders receiving equity in Coeptis in exchange for 9,000 U.S.-based Dogecoin mining machines [1] - The transaction is expected to close in the third quarter of 2025, pending regulatory approvals and shareholder consent [1] Leadership Changes - Post-merger, Z Squared executives will lead the combined entity, with David Halabu as CEO and Michelle Burke as COO [3][4] - Current Coeptis CEO Dave Mehalick will exit the Board of Directors upon closing [3] Strategic Focus - The combined company aims to create the largest publicly-traded entity in the U.S. focused on Dogecoin mining, targeting both retail and institutional investors [5] - Coeptis plans to maintain its biopharmaceutical operations separately after the merger, allowing continued involvement in both sectors [5]

Strategic Collaboration Enhances Access to Cutting-Edge AI, Blockchain Solutions, Biopharma & Defense TechnologiesWEXFORD, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is excited to announce the establishment of a new co-working technology hub in India in partnership with U.S.-based NexGenAI Solutions Group (https://nexgenai.io) and Indian technology firm Ishvara Tech Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39669 Coeptis Therapeutics Holdings, Inc. (Exact name of registrant as specified in it ...

Core Insights - COEPTIS, Inc. has formed a majority-owned subsidiary, GEAR Therapeutics, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for various cancers and therapeutic modalities [1] - The GEAR™ Cell Therapy Platform offers a first-in-class approach to modifying immune cells, aiming to enhance remission rates in patients with hematologic malignancies and other cancers [1] - GEAR-NK cells are designed to be co-administered with targeted monoclonal antibodies, potentially improving treatment outcomes by avoiding neutralization by mAb therapy [2][3] Company Developments - COEPTIS has successfully licensed exclusive worldwide development and commercialization rights to the GEAR platform from VyGen-Bio, Inc., expanding its ownership and capabilities in the biotechnology sector [1][4] - The company is focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, with a commitment to improving patient outcomes through advanced research [5][6] - COEPTIS has established a Technology Division to enhance operational capabilities, incorporating AI-powered marketing software and robotic process automation tools [7] Market Potential - The GEAR technology is expected to address significant therapeutic needs in the market, providing a cost-effective option for patients requiring advanced cancer therapies [4] - The GEAR platform also has the potential to modify hematopoietic stem cells in combination with mAbs, which could improve bone marrow transplant outcomes for hematological malignancies [2]

Core Insights - COEPTIS, Inc. has announced a strategic partnership with Arketyp Valu to integrate advanced digital marketing solutions into the ValuSocial platform, leveraging Verus Coin and blockchain technology [1][2][3] - The ValuSocial platform aims to revolutionize digital marketing by providing a fully immersive environment for targeted campaigns, enhancing user engagement through blockchain security and scalability [2][3] Company Overview - COEPTIS, Inc. is a biopharmaceutical and technology company focused on innovative cell therapy platforms for various diseases, aiming to improve patient outcomes through advanced research and development [4][5] - The company has established a Technology Division to enhance operational capabilities, incorporating AI-powered marketing software and robotic process automation tools from NexGenAI Solutions Group [6] Partnership Details - The collaboration between COEPTIS and Arketyp Valu is set to merge digital marketing innovation with the Verus network's reliable framework, creating a decentralized digital ecosystem [3] - The partnership emphasizes the commitment to drive innovation and redefine digital marketing capabilities, with the ValuSocial platform built on the secure foundations of the Verus Project [3][8] Technology and Market Position - Verus Coin, part of the Verus project, focuses on privacy, security, and scalability, aiming to create a decentralized ecosystem that empowers users and supports application development [7][8] - NexGenAI Affiliates Network is designed to optimize affiliate marketing efforts through automation and advanced analytics, enhancing revenue generation for businesses [9]